Indivumed Therapeutics
Prof. Dr. Hartmut Juhl has a diverse work experience in the field of oncology. Prof. Dr. Hartmut began their career as a Wissenschaftlicher Mitarbeiter at UKE in 1987 and later worked as an Oberarzt at the Chirurgische Universitätsklinik Kiel until 1998. From 1998 to 2002, they served as an Associate Professor at the Georgetown Lombardi Comprehensive Cancer Center. Since 2002, Prof. Dr. Hartmut Juhl has been the CEO of Indivumed Group, a global oncology company specializing in biospecimen and clinical data collection and analysis.
Prof. Dr. Hartmut Juhl completed their higher education at the University of Hamburg, where they obtained a degree in Humanmedizin.
Indivumed Therapeutics
1 followers
Twenty years of innovation, but a vision that remains unchanged. Valued for the standardized collection and analysis of tissue samples that has enabled a truly unique multi-omics database, we are on the verge of reshaping what is possible in the field of precision oncology. We have unlocked an understanding of the molecular reality of cancer at an unparalleled level that is now supporting biomarker and target discovery and validation, drug development, and clinical trial performance. We continue striving for a world where precision therapy is possible for each individual cancer patient. To learn more about our mission, visit www.indivumed-therapeutics.com.